Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgia M Beasley

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Annals of Surgical Oncology|June 23, 2009
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysisAlfredo A Santillan, Keith A Delman, Georgia M Beasley, et al.
Nature Communications|March 26, 2021
Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signalingMichael C Brown, Mubeen M Mosaheb, Malte Mohme, et al.
Molecular Cancer Therapeutics|June 24, 2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapyChristina K Augustine, Hiroaki Toshimitsu, Sin-Ho Jung, et al.
Annals of Surgical Oncology|November 18, 2020
Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in MelanomaNorma E Farrow, Eda K Holl, Jeanne Jung, et al.
Annals of Surgical Oncology|July 22, 2023
Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?Kristen E Rhodin, Sin-Ho Jung, Kelly Elleson, et al.
Journal for Immunotherapy of Cancer|September 29, 2022
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanomaGeorgia M Beasley, Michael C Brown, Norma E Farrow, et al.
Journal of the American College of Surgeons|May 30, 2009
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the USGeorgia M Beasley, Abigail Caudle, Rebecca P Petersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced MelanomaApril K S Salama, Manisha Palta, Christel N Rushing, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 9, 2021
Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival AnalysisAvani M Kolla, Gerardo A Vitiello, Erica B Friedman, et al.
Journal of the American Academy of Dermatology|May 19, 2022
Patterns of recurrence and prognosis in pathologic stage I and II Merkel cell carcinoma: A multicenter, retrospective cohort analysisAndrew D Tieniber, Adrienne B Shannon, Michael J Carr, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Annals of Surgical Oncology|June 23, 2009
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysisAlfredo A Santillan, Keith A Delman, Georgia M Beasley, et al.
Nature Communications|March 26, 2021
Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signalingMichael C Brown, Mubeen M Mosaheb, Malte Mohme, et al.
Molecular Cancer Therapeutics|June 24, 2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapyChristina K Augustine, Hiroaki Toshimitsu, Sin-Ho Jung, et al.
Annals of Surgical Oncology|November 18, 2020
Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in MelanomaNorma E Farrow, Eda K Holl, Jeanne Jung, et al.
Annals of Surgical Oncology|July 22, 2023
Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?Kristen E Rhodin, Sin-Ho Jung, Kelly Elleson, et al.
Journal for Immunotherapy of Cancer|September 29, 2022
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanomaGeorgia M Beasley, Michael C Brown, Norma E Farrow, et al.
Journal of the American College of Surgeons|May 30, 2009
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the USGeorgia M Beasley, Abigail Caudle, Rebecca P Petersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced MelanomaApril K S Salama, Manisha Palta, Christel N Rushing, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 9, 2021
Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival AnalysisAvani M Kolla, Gerardo A Vitiello, Erica B Friedman, et al.
Journal of the American Academy of Dermatology|May 19, 2022
Patterns of recurrence and prognosis in pathologic stage I and II Merkel cell carcinoma: A multicenter, retrospective cohort analysisAndrew D Tieniber, Adrienne B Shannon, Michael J Carr, et al.
Pageof 13